$CALTX News
Last published 2y ago
- 2y agoCALTCALTXCalliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA NephropathyPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the European Commission has granted a full...
- 2y agoCALTCALTXCalliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA NephropathyPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the European Commission has granted a full...
- 2y agoCALTCALTXLaunch of Phase 3 clinical trial with Nefecon in JapanPR NewswireCalliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ STOCKHOLM: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ...
- 2y agoCALTCALTXCalliditas provides setanaxib patent updatePR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office ...
- 2y agoCALTCALTXCalliditas provides setanaxib patent updatePR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office ...
- 2y agoCALTCALTXCalliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathyPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced that the Committee for Medicinal Products for...
- 2y agoCALTCALTXCalliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathyPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced that the Committee for Medicinal Products for...
- 2y agoCALTCALTXCalliditas Therapeutics Presents Data at the 61st European Renal Association CongressPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced the presentations of an additional efficacy...
- 2y agoCALTCALTXCalliditas Therapeutics Presents Data at the 61st European Renal Association CongressPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced the presentations of an additional efficacy...
- 2y agoCALTXCalliditas Q1 report, January - March 2024PR NewswireCalliditas Therapeutics AB (NASDAQ: CALTX) (STOCKHOLM: CALTX): Target market expansion following full approval in the US JANUARY - MARCH 2024...
- 2y agoCALTXCalliditas Q1 report, January - March 2024PR NewswireCalliditas Therapeutics AB (NASDAQ: CALTX) (STOCKHOLM: CALTX): Target market expansion following full approval in the US JANUARY - MARCH 2024...
- 2y agoCALTCALTXIn-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of ActionPR NewswireCalliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced that it will hold an in-person and virtual R&D day ...
- 2y agoCALTCALTXIn-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of ActionPR NewswireCalliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced that it will hold an in-person and virtual R&D day ...
- 2y agoCALTCALTXCalliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in StockholmPR NewswireCalliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ STOCKHOLM: CALTX) ("Calliditas"), today announced upcoming data presentations and a sponsored...
- 2y agoCALTCALTXCalliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in StockholmPR NewswireCalliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ STOCKHOLM: CALTX) ("Calliditas"), today announced upcoming data presentations and a sponsored...
- 2y agoCALTCALTXCalliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in ChinaPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announces that its partner Everest Medicines (HKEX: 1952.HK) ...
- 2y agoCALTCALTXCalliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in ChinaPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announces that its partner Everest Medicines (HKEX: 1952.HK) ...
- 2y agoCALTCALTXCalliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxibPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced data from the proof-of-concept Phase 2 trial...
- 2y agoCALTCALTXCalliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxibPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced data from the proof-of-concept Phase 2 trial...
- 2y agoCALTCALTXCalliditas Therapeutics' 2023 Annual Report PublishedPR NewswireCalliditas Therapeutics AB (NASDAQ: CALT), (NASDAQ STOCKHOLM: CALTX) ("Calliditas") today announces that the Annual Report for 2023 now is available...
- 2y agoCALTCALTXCalliditas Therapeutics' 2023 Annual Report PublishedPR NewswireCalliditas Therapeutics AB (NASDAQ: CALT), (NASDAQ STOCKHOLM: CALTX) ("Calliditas") today announces that the Annual Report for 2023 now is available...
- 2y agoCALTCALTXCalliditas Announces Positive NefIgArd Open Label Extension ResultsPR NewswireCalliditas Therapeutics AB (NASDAQ: CALT), (NASDAQ STOCKHOLM: CALTX) ("Calliditas") today announced that the global open-label extension (OLE) study...
- 2y agoCALTCALTXCalliditas Announces Positive NefIgArd Open Label Extension ResultsPR NewswireCalliditas Therapeutics AB (NASDAQ: CALT), (NASDAQ STOCKHOLM: CALTX) ("Calliditas") today announced that the global open-label extension (OLE) study...
- 2y agoCALTCALTXCalliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024PR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced additional data analyses from the 2-year Phase 3...
- 2y agoCALTCALTXCalliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024PR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced additional data analyses from the 2-year Phase 3...
- 2y agoCALTCALTXCalliditas Therapeutics to Attend Conferences in AprilPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today...
- 2y agoCALTCALTXCalliditas Therapeutics to Attend Conferences in AprilPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today...
- 2y agoCALTCALTXCalliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos AiresPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced upcoming data presentations, as well as a...
- 2y agoCALTCALTXCalliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos AiresPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced upcoming data presentations, as well as a...
- 2y agoCALTCALTXCalliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatmentPR NewswireCalliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced that the Company has received a Notice of...
- 2y agoCALTCALTXCalliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatmentPR NewswireCalliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced that the Company has received a Notice of...
- 2y agoCALTCALTXEverest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®PR NewswireEverest Medicines (HKEX 1952.HK, "Everest", or the "Company")'s licensing partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX)...
- 2y agoCALTCALTXCalliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®PR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ('Calliditas') today announced that the FDA has granted an orphan drug...
- 2y agoCALTCALTXCalliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®PR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ('Calliditas') today announced that the FDA has granted an orphan drug...
- 2y agoCALTCALTXCalliditas Therapeutics to Attend Investor Conferences in MarchPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) and (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today ...
- 2y agoCALTCALTXCalliditas Therapeutics to Attend Investor Conferences in MarchPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) and (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today ...
- 2y agoCALTXCalliditas Year-end report, January - December 2023PR NewswireCalliditas Therapeutics AB (Nasdaq Stockholm: CALTX) 2023: Full approval for TARPEYO in the US; a year of successes OCTOBER – DECEMBER 2023 (COMPARED ...
- 2y agoCALTXCalliditas Year-end report, January - December 2023PR NewswireCalliditas Therapeutics AB (Nasdaq Stockholm: CALTX) 2023: Full approval for TARPEYO in the US; a year of successes OCTOBER – DECEMBER 2023 (COMPARED ...
- 2y agoCALTCALTXCalliditas provides patent updatePR NewswireCalliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office...
- 2y agoCALTCALTXCalliditas provides patent updatePR NewswireCalliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office...
- 2y agoCALTCALTXCalliditas Therapeutics appoints Maria Törnsén as President North AmericaPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today...
- 2y agoCALTCALTXCalliditas Therapeutics appoints Maria Törnsén as President North AmericaPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today...
- 2y agoCALTCALTXCalliditas to present at JP Morgan Healthcare ConferencePR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that management will present at and participate in ...
- 2y agoCALTCALTXCalliditas to present at JP Morgan Healthcare ConferencePR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that management will present at and participate in ...
- 2y agoCALTCALTXCalliditas refinances existing term loan with Euro 92 million senior secured facility with Athyrium CapitalPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) and (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company has signed and fully drawn a...
- 2y agoCALTCALTXCalliditas refinances existing term loan with Euro 92 million senior secured facility with Athyrium CapitalPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) and (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company has signed and fully drawn a...
- 2y agoCALTCALTXEverest Medicines' Partner Calliditas Therapeutics Announces Nefecon® the Only FDA-approved Treatment for IgA Nephropathy to Significantly Slow Kidney Function DeclinePR NewswireEverest Medicines (HKEX 1952.HK, "Everest", or the "Company")'s licensing partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX)...
- 2y agoCALTCALTXCalliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney functionPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced that the U.S. Food and Drug Administration (FDA)...
- 2y agoCALTCALTXCalliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney functionPR NewswireCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced that the U.S. Food and Drug Administration (FDA)...
- 2y agoCALTCALTXCalliditas Receives Notice of Allowance for United States Patent Application Covering TARPEYO®PR NewswireCalliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that it has received a Notice of Allowance from the ...